Becton Dickinson (BDX)

Health Care · $57.9B market cap · SEC CIK 0000010795

Next reports on Feb 8, 2027, with analysts expecting $2.40 in earnings per share.

52-week range $137.36 to $216.74. 2% below its 52-week high and 55% above its low.

The case for BDX

• Moves less than the market (beta 0.20).
• Pays a modest 1.6% dividend.
• Within 2% of its 52-week high: the trend is up.
• Up 54.0% over the past year.

The case against

• Expensive for its growth: 50.5× earnings, where 0% a year of growth plus a 1.6% dividend would justify about 10×.
• Revenue fell 7.4% year over year.
• Earnings per share down 28.8%.
• Long-term debt of $17.6B would take 5 years of operating cash flow to repay.
• Return on equity of only 5%.
• Current liabilities exceed current assets (ratio 0.87).

What the score is made of

Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. The score is where that blend places it in the S&P 500. It describes the last filing and the current price. It is not a forecast.

• Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.

The financials

The financials, five years deep

Pulled from Becton Dickinson's XBRL filings on SEC EDGAR. Italic rows are worked out from the others.

What Becton Dickinson says it does

Becton, Dickinson and Company (also referred to herein as "BD") was incorporated under the laws of the State of New Jersey in November 1906, as successor to a New York business started in 1897. BD’s executive offices are located at 1 Becton Drive, Franklin Lakes, New Jersey 07417-1880, and its telephone number is (201) 847-6800. All references in this Form 10-K to "BD", "the Company", "we", "our" or "us" refer to Becton, Dickinson and Company and its domestic and foreign subsidiaries, unless otherwise indicated by the context. BD is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. We provide customer solutions that are focused on improving medication management and…

Risk factors BDX lists in its 10-K

• Global economic conditions, including inflation and supply chain disruptions, could continue to adversely affect our operations
• Our international operations subject us to certain business risks
• The medical technology industry is very competitive
• Reductions in customers’ research budgets or government funding may adversely affect our business
• Our future growth is dependent in part upon the development of new products, and there can be no assurance that such products will be developed
• We are subject to foreign currency exchange risk
• We need to attract and retain key employees to be competitive
• Cybersecurity incidents and breaches or breakdowns of our information and technology systems or infrastructure could have a material adverse effect on our operations
• A reduction or interruption in the supply of certain raw materials and components could adversely affect our operating results
• Interruption of our manufacturing or sterilization operations could adversely affect our business
• Cost volatility could adversely affect our operations
• Climate change and related sustainability efforts, or legal, regulatory or market measures to address these efforts, could adversely affect our business, financial condition or results of operations
• We are subject to extensive regulation
• Defects or quality issues associated with our products and related regulatory actions could adversely affect our results of operations and financial statements
• Our operations are dependent in part on patents and other intellectual property assets
• We may not be able to service all of our indebtedness
• The agreements that govern our indebtedness impose restrictions that may affect our ability to operate our businesses
• The proposed combination of our Biosciences and Diagnostic Solutions business with Waters may not be completed, on the currently contemplated timeline or at all
• The announcement and pendency of the combination of our Biosciences and Diagnostic Solutions business with Waters could cause disruptions in our business
• We may not realize some or all of the expected benefits of the combination of our Biosciences and Diagnostic Solutions business with Waters
• We cannot guarantee that any of our strategic acquisitions, investments or alliances will be successful
• Natural disasters, public health crises, war and other events beyond our control could disrupt our business and adversely affect our future revenues and operating income
• Information About our Executive Officers

Filings

Other Health Care companies